If you would like to book a free 20-minute eligibility assessment for this study, you can Book here. Note: If you book a review, please mention honahlee. We do not have a financial relationship with Medlab, it is for record keeping purposes only.
According to TGA data, chronic pain is the first prescribed condition for medical cannabis in Australia. However, while there is evidence that cannabis can benefit pain, many doctors still do not believe in the plant’s analgesic properties. The solution to the doctor’s problem is more clinical trials.
In this article, you will learn about a clinical study conducted by Medlab Clinical, a resource for medical cannabis. We were fortunate to speak with the very interested and knowledgeable Courtney Fletcher, clinical trial coordinator at Medlab Clinical, about this study. In case you want to go further, here is an index:
Background on the study of cannabis and chronic pain
The product used in this study is a cannabis drug that is prescribed by a healthcare practitioner for pain relief. The product is an oral nanoparticle atomizer, which means that the mist delivers the product to the patient’s mouth. The delivery platform is called NanoCelle®, which allows the active ingredient to be absorbed faster and more effectively into the bloodstream. In this case, the ingredients are hemp CBD and THC.
The observational study is a national, multicenter study conducted in Australia. It is intended for patients who are about to start treatment with a cannabis-based NanoCelle® formula for the management of cancer-related or non-cancer-related pain. During the 12-month study, Medlab will investigate clinical and educational changes to a drug called NanaBis™.
The study began in May 2019, and the expected completion date is May 2024. The goal is to enroll 2,000 adult patients of at least 18 years of age with a diagnosis of cancer-related or non-cancer-related pain.
Why chronic pain?
Chronic pain is the most common cause For patients who get scripts for medical cannabis. This is often because there are limited other ways to control chronic pain (which contributes significantly to the disease burden in about half of cancer patients).
Poor management of chronic pain can negatively affect patients’ quality of life. People who don’t respond well to opioids or who experience severe side effects from using conventional analgesics (pain relievers) need other treatment options.
Study helps learn more about treatments for chronic pain, a condition that affects 1 in 5 Australians, can positively affect our society.
Current insights from the study
over there primary The first report. Here are some important data:
- More than 900 patients were enrolled
- Positive improvements in sleep
- Positive mood improvement
- Positive improvements in activity scores
- Significant decrease in pain levels
Participant Eligibility Requirements
- 18+ years old
- Eligible for a cannabis-based NanoCelle® formula for the management of cancer-related or non-cancer-related pain;
- You should refrain from using other cannabis products;
- Willing to participate for up to 12 months (usually about 4 months);
- Complete a monthly feedback/feedback session;
Participation in the study: what to expect
If you would like to know if you are eligible to participate in this study, you can visit Medlab’s Observational study Page and booking screening and eligibility assessment.
During the initial visit, your doctor will examine you to ensure your suitability to participate in the trial. The first visit takes about 30 minutes.
If you qualify and decide to participate in the trial, you will need to complete two questionnaires about your pain and quality of life. You will be instructed by the clinical team on how to complete the questionnaires.
Once you have been prescribed the study, you will be asked to visit the clinic once per month for a maximum of 12 months (possibly around 4 months). At each visit, you will provide information about the administration and effectiveness of the product in managing pain.
The cost of participating in the trial
Study participants will receive a Medlab cannabis product at a subsidized price (50% discount) for the duration of their participation in the study. However, the cost of doctor visits will be at your expense.
After the clinical trial, if you decide to continue using a Medlab product for symptom control, the product will be purchasable at a non-subsidised price.
If you want to book a free 20-minute evaluation of eligibility, you can Book here. Note: If you book a review, please mention honahlee. We do not have a financial relationship with Medlab, it is for record keeping purposes only.